{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-146134","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.840370+00:00","generated_at":"2026-05-18T19:48:55.920910+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M","bullets":["Up to $750M total payments including $85M upfront/option exercise payments.","Tiered royalties ranging from high-single-digit to mid-teens on net sales.","Kymera leads all research; Gilead obtains global development/manufacturing/commercialization rights.","CDK2 degraders target breast cancer and other solid tumors.","Agreement announced June 25, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-146134","json":"https://secwatch.observer/filing/0001193125-25-146134.json","markdown":"https://secwatch.observer/filing/0001193125-25-146134.md","text":"https://secwatch.observer/filing/0001193125-25-146134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525146134/0001193125-25-146134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525146134/d923971d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:48:55.920910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}